Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | PTGIR | P43119 | 2/20 | 0.31 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.30 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13195396 | 0.93 | LMNA (0.37) | MGLLLMNAPARP15PARP10PARP2 | |
| SCHEMBL1796877 | 0.93 | LMNA (0.40) | MGLLLMNAPARP15PARP10 | |
| SCHEMBL2411964 | 0.92 | LMNA (0.42) | MGLLLMNAPARP15PARP10 | |
| SCHEMBL2355265 | 0.89 | CCNE1 (0.30) | CCNE1CDK2GSK3B | |
| SCHEMBL22439268 | 0.82 | MGLL (0.30) | MGLL | |
| SCHEMBL18748771 | 0.79 | ALDH1A1 (0.31) | — | |
| SCHEMBL14063664 | 0.79 | MGLL (0.33) | MGLLCCNE1CDK2GSK3B | |
| SCHEMBL31326995 | 0.78 | MGLL (0.31) | MGLL | |
| SCHEMBL4664384 | 0.78 | MGLL (0.38) | MGLL | |
| SCHEMBL8035936 | 0.77 | MGLL (0.32) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988561-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPharma Ltd. (KY) | 2022-04-27 | — | — | EP | disclosed |
| US-11312703-B2 | Reactive oxygen species scavengers and use for treating diseases | XWPharma Ltd. (KY) | 2022-04-26 | — | — | US | disclosed |
| EP-3679051-B1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPHARMA LTD (KY) | 2021-12-29 | — | — | EP | disclosed |
| US-20210061791-A1 | REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES | XWPharma Ltd. (KY) | 2021-03-04 | — | — | US | disclosed |
| US-10889572-B2 | Reactive oxygen species scavengers and use for treating diseases | XW LABORATORIES INC. (KY) | 2021-01-12 | — | — | US | disclosed |
| US-20200199108-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XWPharma Ltd. (KY) | 2020-06-25 | — | — | US | disclosed |
| WO-2019041361-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | XW LABORATORIES, INC. (CN) | 2019-03-07 | — | — | WO | disclosed |
| EP-2693882-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2693882-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-2760855-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AS WELL AS THEIR USE IN TREATING TYPE-2 DIABETES | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| WO-2012138845-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-10-11 | — | — | WO | disclosed |
| US-8058259-B2 | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058259-B2 | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-7951823-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-31 | — | — | US | disclosed |
| US-20090162282-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| US-20090162282-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| EP-2027143-A2 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007137080-A2 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2007-11-29 | — | — | WO | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889572-B2 | Reactive oxygen species scavengers and use for treating diseases | GSR, TXNRD2, GPX1 | MGLL 4066/4885LMNA 3016/4885PTGIR 540/4885 |
| US-20090162282-A1 | SUBSTITUTED 4--PIPERIDINE-1-CARBOXYLIC ACID ESTERS AS A2AR AGONISTS | ADORA2A, ADORA3, ADORA1 | MGLL 3083/4885LMNA 2698/4885PTGIR 133/4885 |
| US-20210061791-A1 | REACTIVE OXYGEN SPECIES SCAVENGERS AND USE FOR TREATING DISEASES | GSR, TXNRD2, GPX1 | MGLL 4066/4885LMNA 3016/4885PTGIR 540/4885 |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | MGLL 3534/4885LMNA 1370/4885PTGIR 1138/4885 |
| US-20200199108-A1 | PREPARATION AND USE OF REACTIVE OXYGEN SPECIES SCAVENGER | GPX1, SOD1, GPX4 | MGLL 4037/4885LMNA 2425/4885PTGIR 688/4885 |
| US-11312703-B2 | Reactive oxygen species scavengers and use for treating diseases | GSR, TXNRD2, GPX1 | MGLL 4066/4885LMNA 3016/4885PTGIR 540/4885 |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | MGLL 3534/4885LMNA 1370/4885PTGIR 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.